Oluminant ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 107 | 若年性特発性関節炎 | 1 |
107. 若年性特発性関節炎
臨床試験数 : 441 / 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004518-24-IT (EUCTR) | 17/05/2019 | 17/06/2021 | A study of Baricitinib compared to placebo in children with Juvenile Idiopathic Arthritis (JIA) | A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA) - na | Juvenile Idiopathic Arthritis (JIA) MedDRA version: 23.1;Level: PT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: olumiant Product Name: Olumiant Product Code: [LY3009104] INN or Proposed INN: BARICITINIB Other descriptive name: baricitinib Trade Name: oluminant Product Name: Olumiant Product Code: [LY3009104] INN or Proposed INN: BARICITINIB Other descriptive name: Baricitinib Product Name: Olumiant Product Code: [LY3009104] INN or Proposed INN: BARICITINIB Other descriptive name: baricitinib Product Name: Olumiant Product Code: [LY3009104] INN or Proposed INN: BARICITINIB Other descriptive name: baricitinib | ELI LILLY & COMPANY, LILLY CORPORATE CENTER | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 225 | Phase 3 | Czechia;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;India;France;Czech Republic;Mexico;Argentina;Poland;Brazil;Belgium;Australia;Denmark;Germany;China;Japan |